Home›Legal›Semaglutide in Texas
Semaglutide in Texas: Legal Status & Provider Guide (2026)
Quick Answer
Semaglutide is a prescription substance in the United States. Semaglutide is an FDA-approved drug. Compounded versions were temporarily permitted during a drug shortage that ended in early 2025. Current federal law generally prohibits 503A/503B compounding of semaglutide except for narrow clinical exceptions. Patients should verify their provider's legal basis for offering compounded semaglutide. In Texas, compounding is governed by the Texas State Board of Pharmacy (TSBP). In Texas, physician assistants and nurse practitioners with prescriptive authority can prescribe compounded medications including peptides. Prescribers must hold an active Texas license. Telemedicine prescribing of controlled substances and certain compounded medications is permitted under Texas Medical Board rules with specific conditions.
Federal Legal Status
FDA Approval Status
FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral, type 2 diabetes, 2019). Compounded semaglutide was permitted during shortage but FDA declared shortage resolved in March 2025.
Compounding Pharmacy Rules (Federal)
Compounding of semaglutide was broadly permitted under shortage exemptions through early 2025. Following FDA's March 2025 shortage resolution declaration, 503B outsourcing facilities had a wind-down period through April 2025, and 503A pharmacies through May 2025. As of mid-2025, compounded semaglutide is generally prohibited except for specific patient needs (e.g., documented allergy to an inactive ingredient in the commercially available product) under a valid prescription.
Also Known As
Ozempic · Wegovy · Rybelsus
Primary Research Areas
- Weight management
- Type 2 diabetes
- Cardiovascular risk reduction
- Metabolic health
Texas Pharmacy Board & Compounding Rules
Regulator
Compounding Overview
Texas is home to one of the largest compounding pharmacy industries in the country, with detailed rules set by the Texas State Board of Pharmacy (TSBP). Texas 503A pharmacies may compound non-FDA-approved peptides under certain conditions, though federal FDA guidance takes precedence for pharmacies participating in the national regulatory framework. Texas-specific rules address sterile compounding standards, USP 797 compliance, and registration requirements for non-resident pharmacies shipping into the state.
Notable Rules
- Texas TSBP requires sterile compounding facilities to comply with USP 797 standards.
- Non-resident (out-of-state) pharmacies shipping compounded products into Texas must be registered with the TSBP.
- Texas prohibits the sale of prescription-only compounded products without a valid prescription.
- The Texas Medical Board regulates prescribing standards for telemedicine encounters including peptide programs.
Prescribing Requirements in Texas
In Texas, physician assistants and nurse practitioners with prescriptive authority can prescribe compounded medications including peptides. Prescribers must hold an active Texas license. Telemedicine prescribing of controlled substances and certain compounded medications is permitted under Texas Medical Board rules with specific conditions.
About Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed by Novo Nordisk. It is FDA-approved for type 2 diabetes and chronic weight management and is among the most studied compounds in contemporary metabolic medicine.
For more research information, mechanism of action, and provider availability, see the Semaglutide research profile on PeptideBase.
Frequently Asked Questions
- Is compounded semaglutide legal in 2026?
- FDA declared the semaglutide shortage resolved in March 2025. After wind-down periods, compounding of semaglutide is generally prohibited for 503A and 503B facilities. Narrow exceptions exist for documented allergies to commercially available formulations. Patients should ask providers for the specific legal basis for any compounded product.
- What is the difference between Ozempic, Wegovy, and compounded semaglutide?
- Ozempic (0.5–2 mg weekly injection) is approved for type 2 diabetes. Wegovy (2.4 mg weekly injection) is approved for chronic weight management. Compounded semaglutide was chemically equivalent but manufactured by compounding pharmacies — a practice now restricted following the shortage resolution.
Semaglutide Providers in Texas
No providers currently listed in Texas for Semaglutide. Browse the full directory to find providers offering Semaglutide.
Browse all Semaglutide providers →Semaglutide Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare Semaglutide legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .